A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma

Oral Oncology

Volumn 48, Issue 5, 2012, Pages 441-444

  Yau, T K ^a   Shum, T ^a   Lee, A W M ^a   Yeung, M W ^a   Ng, W T ^a   Chan, L ^a  

^a PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

Author keywords

Chemotherapy; Cisplatin; Metastasis; Nasopharyngeal carcinoma; Neoplasm recurrence; Pemetrexed

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; FOLIC ACID; PEMETREXED;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; DISTANT METASTASIS; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; FATIGUE; GENE DOSAGE; HEARING IMPAIRMENT; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SENSORY NEUROPATHY; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR RECURRENCE; VITAMIN SUPPLEMENTATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84860013938     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2011.12.001     Document Type: Article

References (24)

1. Hong Kong Cancer Registry (http://www3.ha.org.hk/cancereg), as assessed on 4th Oct 2011.
2. Teo PM, Kwan WH, Lee WY, Leung SF, Johnson PJ. Prognosticators determining survival subsequent to distant metastases from nasopharyngeal carcinoma. Cancer 1996;77(12):2423-31. (Pubitemid 26169137)
3. Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of the nasopharyngeal type. J Clin Oncol 2000;18(6):1324-30. (Pubitemid 30159852)
4. Foo KF, Tan EH, Leong SS, Wee JT, Tan T, Fong KW, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 2002;13(1):150-6. (Pubitemid 34436739)
5. Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 2003;39(4):361-6. (Pubitemid 36379343)
6. Yeo W, Leung TW, Chan AT, Chiu SK, Yu P, Mok TS, et al. A phase II study combination of paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer 1998;34(13):2027-31. (Pubitemid 28546936)
7. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(9):1589-97. (Pubitemid 41079796)
8. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21(14):2636-44. (Pubitemid 46606305)
9. Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 2001;85(5):649-55. (Pubitemid 32929458)
10. Hui EP, Leung SF, Au JS, Zee B, Tung S, Chua D, et al. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong nasopharyngeal carcinoma study group. Cancer 2004;101(2):300-6.
11. Au E, Ang PT. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 1994;5(1):87-9. (Pubitemid 24049859)
12. Su WC, Chen TY, Kao RH, Tsao CJ. Chemotherapy with cisplatin and continuous infusion of 5-fluorouracil and bleomycin for recurrent and metastatic nasopharyngeal carcinoma in Taiwan. Oncology 1993;50(4):205-8.
13. Taamma A, Fandi A, Azli N, Wibault P, Chouaki N, Hasbini A, et al. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer 1999;86(7):1101-8. (Pubitemid 29446990)
14. Siu LL, Czaykowski PM, Tannock IF. Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J Clin Oncol 1998;16(7):2514-21. (Pubitemid 28309049)
15. Hasbini A, Mahjoubi R, Fandi A, Chouaki N, Taamma A, Lianes P, et al. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann Oncol 1999;10(4):421-5. (Pubitemid 29236419)
16. Barton-Burke M. Gemcitabine: a pharmacologic and clinical overview. Cancer Nurs 1999;22(2):176-83. (Pubitemid 29352696)
17. Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck EORTC early clinical trials group. Ann Oncol 1994;5(6):543-7. (Pubitemid 24223508)
18. Ngan RK, Yiu HH, Lau WH, Yau S, Cheung FY, Chan TM, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol 2002;13(8):1252-8. (Pubitemid 34960134)
19. Chua D, Wei WI, Sham JS, Au GK. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. Jpn J Clin Oncol 2008;38(4):244-9. (Pubitemid 351583987)
20. Li YH, Wang FH, Jiang WQ, Xiang XJ, Deng YM, Hu GQ, et al. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol 2008;62(3):539-44.
21. Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23(15):3568-76.
22. Chua DT, Wei WI, Wong MP, Sham JS, Nicholls J, Au GK. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck 2008;30(7):863-7. (Pubitemid 352008945)
23. Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007;25(24):3766-73. (Pubitemid 47372619)
24. Villaflor VM, Haraf D, Salama JK, Kocherginsky M, Langerman A, Gomez-Abuin G, et al. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol 2011;22(11):2501-7.